Felice Lightstone | 20-ERD-065
To identify suitable candidate compounds for further development into antiviral drugs for Coronavirus disease 2019, we will design and implement a large-scale platform for screening small molecules that entails (1) using computational methods to predict binding, safety, and pharmacokinetic outcomes, and (2) experimentally testing the top candidates for efficacy against viral proteins. This research responds to the urgent need to address the Coronavirus pandemic and supports long-term national efforts to develop countermeasures to biological threats.
Publications, Presentations, and Patents
Lightstone, F., et. al. 2020. Lawrence Livermore National Laboratory Covid-19 Therapeutic Design (covid19drugscreen.llnl.gov). LLNL-WEB-808974